Monash IVF H1 FY26 slides: market share declines amid sector softness

Monash IVF Group Ltd (ASX:MVF) reported its first-half fiscal 2026 results on February 26, 2026, revealing a challenging period marked by market share erosion and industry-wide softness in the Australian assisted reproductive services sector, particularly in Victoria and New South Wales, with new CEO Dr. Victoria Atkinson outlining strategic priorities to address the performance decline. The company posted revenue of $137.9 million, down 1.8% year-over-year, while maintaining profitability at the upper end of its guidance range with underlying net profit after tax of $10.4 million. The domestic IVF market share declined significantly by 2.5 percentage points to 19.0%, down from 21.5% in the prior corresponding period, as stimulated cycle volumes fell 9.9%. Despite these headwinds, Monash IVF declared a fully franked interim dividend of 1.2 cents per share and maintained its full-year underlying NPAT guidance of $20 million. The financial performance decline was primarily driven by market share loss, which cost the company $8.3 million in revenue, partially offset by price increases in select markets and growth in international and genetics operations. Underlying EBITDA declined 15.3% to $30.2 million, with the EBITDA margin contracting 3.5 percentage points to 22.0%. The earnings decline was more pronounced than the revenue decrease, reflecting operational deleverage and cost pressures. The company experienced particular weakness in Victoria and New South Wales, its two largest markets, which Dr. Atkinson identified as requiring immediate attention. The gap between underlying and reported earnings reflects non-regular items including commissioning costs, restructuring expenses, and class action-related costs. Market share challenges represent a significant strategic concern for Monash IVF, particularly given the company's #2 ranking in the Australian stimulated cycle market. The competitive pressure was most acute in New South Wales and Victoria, where the company faces both established competitors and new market entrants. South Australia was the only exception where the company maintained its market position. Despite these challenges, Monash IVF maintained its clinical leadership position, with pregnancy rates continuing to improve. The company's clinical pregnancy rate for women aged under 43 years reached 40.7% in calendar year 2025, up from 40.1% in 2024. The genetics division demonstrated strong momentum, with total embryos tested for chromosomal abnormality (PGT-A) increasing 31% in the first half, while international operations showed positive trends with Singapore stimulated cycles increasing 6.4%, Bali cycles more than doubling, and Johor Bahru cycles rising 26%.